Discovery and Validation of a Compound to Target Ewing’s Sarcoma
Authors:
- Ellie Esfandiari NazzaroENEllie Esfandiari Nazzaro
- Fahad Y. SabeiFSFahad Y. Sabei
- Walter K. VogelWVWalter K. Vogel
- Mohamad NazariMNMohamad Nazari
- Katelyn S. NicholsonKNKatelyn S. Nicholson
- Philip R. GafkenPGPhilip R. Gafken
- Olena TaratulaOTOlena Taratula
- Oleh TaratulaOTOleh Taratula
- Monika A. DavareMDMonika A. Davare
- Mark LeidMLMark Leid
Open Access
- 24 September 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1553
Abstract
Ewing’s sarcoma, characterized by pathognomonic t (11; 22) (q24; q12) and related chromosomal ETS family translocations, is a rare aggressive cancer of bone and soft tissue. Current protocols that include cytotoxic chemotherapeutic agents effectively treat localized disease; however, these aggressive therapies may result in treatment-related morbidities including second-site cancers in survivors. Moreover, the five-year survival rate in patients with relapsed, recurrent, or metastatic disease is less than 30%, despite intensive therapy with these cytotoxic agents. By using high-throughput phenotypic screening of small molecule libraries, we identified a previously uncharacterized compound (ML111) that inhibited in vitro proliferation of six established Ewing’s sarcoma cell lines with nanomolar potency. Proteomic studies show that ML111 treatment induced prometaphase arrest followed by rapid caspase-dependent apoptotic cell death in Ewing’s sarcoma cell lines. ML111, delivered via methoxypoly(ethylene glycol)-polycaprolactone copolymer nanoparticles, induced dose-dependent inhibition of Ewing’s sarcoma tumor growth in a murine xenograft model and invoked prometaphase arrest in vivo, consistent with in vitro data. These results suggest that ML111 represents a promising new drug lead for further preclinical studies and is a potential clinical development for the treatment of Ewing’s sarcoma.Keywords
Funding Information
- Oregon Health and Science University (N/A)
- Sam Day Foundation (N/A)
- National Institutes of Health (R01CA237569, R37CA234006, P30CA015704)
This publication has 98 references indexed in Scilit:
- Molecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional TargetsAnnual Review of Pathology: Mechanisms of Disease, 2012
- APCcdh1 Mediates Degradation of the Oncogenic Rho-GEF Ect2 after MitosisPLOS ONE, 2011
- Recent advances in the molecular pathogenesis of Ewing's sarcomaOncogene, 2010
- Regulated Degradation of Spindle Assembly Factors by the Anaphase-Promoting ComplexMolecular Cell, 2010
- Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein FJournal of Cell Science, 2010
- Identification of a physiological E2 module for the human anaphase-promoting complexProceedings of the National Academy of Sciences, 2009
- A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcomaNature Medicine, 2009
- RCS1, a substrate of APC/C, controls the metaphase to anaphase transitionProceedings of the National Academy of Sciences, 2008
- The Processivity of Multiubiquitination by the APC Determines the Order of Substrate DegradationCell, 2006
- An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseJournal of the American Society for Mass Spectrometry, 1994